Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea

Morrison, L.Katherine; Harrison, Anna L.; Krishnaswamy, Padma; Kazanegra, Radmila; Clopton, Paul; Maisel, Alan S.

doi:10.1016/s0735-1097(01)01744-2

Cited by 555 publications

(278 citation statements)

References 25 publications

Supporting

Mentioning

247

Contrasting

Unclassified

Order By: Relevance

“…1 The main reasons why CHF is less frequently detected are the non-specific symptoms, comorbidity and limited access to echocardiography. [2][3][4] On the other hand, in some residents the diagnosis of CHF is made while their symptoms are caused by other disorders. Both undetected diagnosis and incorrect diagnosis will lead to inadequate treatment of the underlying disease, and will impair the quality of life.…”

mentioning

confidence: 99%

Prevalence and misdiagnosis of chronic heart failure in nursing home residents: the role of B-type natriuretic peptides

Barents¹,

Horst²,

Voors³

et al. 2008

NHJL

View full text Add to dashboard Cite

Background/objectives. Without knowing the exact CHF prevalence, chronic heart failure (CHF) occurs frequently in elderly people both inside and outside nursing homes. For a diagnosis we have to rely on physical examination and additional tests. We therefore run the risk of missing CHF diagnoses or of diagnosing CHF when we should not. Natriuretic peptide assays have emerged as a diagnostic test but their use in nursing home residents is limited. We examined the number of misdiagnoses, the CHF prevalence and the role of natriuretic peptide. Method. Residents in one centre without aphasia, cognitive impairments or metastatic cancer were screened for CHF; the natriuretic peptide levels were measured separately.

show abstract

mentioning

confidence: 99%

Prevalence and misdiagnosis of chronic heart failure in nursing home residents: the role of B-type natriuretic peptides

Barents¹,

Horst²,

Voors³

et al. 2008

NHJL

View full text Add to dashboard Cite

show abstract

“…[7][8][9] Plasma levels of BNP correlate with functional class according to the NYHA and can be used to differentiate cardiac from pulmonary dyspnoea. 10,11 Plasma levels after VAD implantation are thought to give an indication of the extent of unloading of the ventricles. The aim of this study was to investigate whether functional and haemodynamic recovery after implantation of a ventricular assist device in patients with end-stage heart failure is sufficient to warrant the use of them as an alternative to transplantation.…”

mentioning

confidence: 99%

Left ventricular assist device: a functional comparison with heart transplantation

Pruijsten

Jonge²,

Kirkels³

et al. 2008

NHJL

View full text Add to dashboard Cite

Background. A growing number of patients with end-stage heart failure undergo implantation of ventricular assist devices as a bridge to heart transplantation. Objectives. In this study we investigated whether functional and haemodynamic recovery after implantation is sufficient to warrant the use of them as long-term alternative to heart transplantation. Methods. We compared peak VO 2 of a group of patients three months after implantation of a ventricular assist device and three months after heart transplantation. Furthermore, we analysed the degree of haemodynamic recovery, by comparing plasma levels of BNP and creatinine before and after implantation of the device. Results. After implantation of a ventricular assist device, exercise capacity improved considerably; three months after implantation peak VO 2 was 20.0±4.9 ml/kg/min (52% of predicted for age and gender). After heart transplantation exercise capacity improved even further; 24.0±3.9 ml/ kg/min (62% of predicted for age and gender) (p<0.001). In the three months after implantation, BNP plasma levels decreased from 570±307 pmol/l to 31±25 pmol/l and creatinine levels decreased from 191±82 µmol/l to 82±25 µmol/l, indicating significant unloading of the ventricles and haemodynamic recovery. Conclusion. With regard to functional and haemodynamic recovery, the effect of implantation of a ventricular assist device is sufficient to justify its use as an alternative to heart transplantation. (Neth Heart J 2008;16:41-6.)

show abstract

“…In the intermediate or undetermined phase, which has only positive serology and no clinical, electrocardiographic, radiological, or echocardiographic alteration, no investigation exists about BNP measurement using any technique. The technology of the Triage BNP Test (Biosite, San Diego, CA) has already been approved, due to its efficacy and accuracy for determining the serum levels of BNP 6 , and the North American FDA has licensed its use.…”

Section: Discussionmentioning

confidence: 99%

Determinação do peptídeo natriurético cerebral humano em portadores da doença de Chagas

Melo¹,

Parente

Victor

2005

Arq. Bras. Cardiol.

View full text Add to dashboard Cite

Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea

Abstract: Rapid testing of BNP in the ED should help differentiate pulmonary from cardiac etiologies of dyspnea.

Cited by 555 publications

References 25 publications

Prevalence and misdiagnosis of chronic heart failure in nursing home residents: the role of B-type natriuretic peptides

Prevalence and misdiagnosis of chronic heart failure in nursing home residents: the role of B-type natriuretic peptides

Left ventricular assist device: a functional comparison with heart transplantation

Determinação do peptídeo natriurético cerebral humano em portadores da doença de Chagas

Contact Info

Product

Resources

About